Finance

Beta
Lists
NTLA:NASDAQ
Intellia Therapeutics Inc
$12.96
-12.10%
(-1.78) 1D
Jun 5, 2:32:22 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
$14.50
High
$14.79
Low
$12.89
Mkt. cap
1.80B
Avg. vol.
8.03M
Volume
4.70M
52-wk high
$28.25
52-wk low
$7.75
EPS
-$3.53
Beta
1.92
Shares outstanding
139.72M
No. of employees
377
Open
$14.50
High
$14.79
Low
$12.89
Mkt. cap
1.80B
Avg. vol.
8.03M
Volume
4.70M
52-wk high
$28.25
52-wk low
$7.75
EPS
-$3.53
Beta
1.92
Shares outstanding
139.72M
No. of employees
377
Analyst outlook
Analyst Ratings
Based on 18 analysts giving stock ratings to NTLA in the past 3 months
Buy
Buy
8
Hold
8
Sell
2
12 month forecast
Based on 18 Wall Street analysts offering 12 month price targets for NTLA in the last 3 months.
Highest
Current $12.96
$49.00 (+277.94%)
Average
$21.06 (+62.44%)
Lowest
$8.00 (-38.30%)
News stories
From sources across the web
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
14.24M
13.78M
23.02M
15.05M
Cost of goods sold
80.53M
78.95M
73.63M
80.74M
Cost of revenue
80.53M
78.95M
73.63M
80.74M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.71M
46.31M
48.10M
34.84M
Operating expense
43.71M
46.31M
48.10M
34.84M
Total operating expenses
124.24M
125.26M
121.73M
115.58M
Operating income
-110.00M
-111.48M
-98.71M
-100.53M
Other non operating income
-
-
-
-
EBT including unusual items
-101.26M
-101.32M
-95.79M
-96.23M
EBT excluding unusual items
-102.59M
-104.76M
-92.23M
-95.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-101.26M
-101.32M
-95.79M
-96.23M
Net profit margin
-710.81%
-735.19%
-416.15%
-639.49%
Earnings per share
-0.98
-0.92
-0.83
-0.81
Interest and investment income
7.40M
6.71M
6.48M
5.20M
Interest expense
-
-
-
-
Net interest expenses
7.40M
6.71M
6.48M
5.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-107.52M
-109.06M
-96.33M
-98.33M
Gain or loss from assets sale
-
-
527.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer